“Whilst we wait for a cure, could Baricitinib act as a potential treatment for 2019-nCoV acute respiratory disease?” TMLEP Member, Justin Stebbing explores.

“Whilst we wait for a cure, could Baricitinib act as a potential treatment for 2019-nCoV acute respiratory disease?” TMLEP Member, Justin Stebbing explores.

TMLEP Member, Justin Stebbing and his team research Baricitinib as a potential treatment for 2019-nCoV.

2019-nCoV is rapidly spreading across all continents and it is clear there is an increasing need for medicines that can aid patients whilst we await a vaccine. Research has shown there are few compounds which are likely to have an effective impact. TMLEP Member, Justin Stebbing explores the effectiveness of Baricitinib, which is predicted to reduce the ability of the virus to infect lung cells.

To read the full papers click below.

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

COVID-19- combining antiviral and anti-inflammatory treatments

Important Note

This article is intended to raise awareness to clinical risk issues in an effort to reduce incidence recurrence and improve patient safety. This is not intended to be relied upon as advice. Facts have been altered to ensure this case is non-identifiable, albeit clinical learning points remain applicable. To request an independent clinical review, please contact admin@tmlep.com or call +44 (0) 203 355 9796.